

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 August 2002 (15.08.2002)

PCT

(10) International Publication Number  
**WO 02/062383 A2**

- (51) International Patent Classification<sup>7</sup>: **A61K 39/395**,  
A61P 25/00, C07K 16/28
- (21) International Application Number: PCT/GB02/00551
- (22) International Filing Date: 8 February 2002 (08.02.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
0103174.9 8 February 2001 (08.02.2001) GB
- (71) Applicant (*for all designated States except US*):  
**SMITHKLINE BEECHAM P.L.C.** [GB/GB]; New  
Horizons Court, Brentford, Middlesex TW8 9EP (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): **IRVING, Elaine,**  
**Alison** [GB/GB]; GlaxoSmithKline, New Frontiers Sci-  
ence Park South, Third Avenue, Harlow, Essex CM19 5AW  
(GB). **VINSON, Mary** [GB/GB]; GlaxoSmithKline, New  
Frontiers Science Park South, Third Avenue, Harlow, Es-  
sex CM19 5AW (GB).
- (74) Agent: **LEAROYD, Stephanie**; Corporate Intellectual  
Property, GlaxoSmithKline CN925.1, 980 Great West  
Road, Brentford, Middlesex TW8 9GS (GB).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR,  
GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent  
(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR,  
NE, SN, TD, TG).
- Published:**  
— *without international search report and to be republished  
upon receipt of that report*
- For two-letter codes and other abbreviations, refer to the "Guid-  
ance Notes on Codes and Abbreviations" appearing at the begin-  
ning of each regular issue of the PCT Gazette.*

(54) Title: NOVEL METHOD OF TREATMENT

(57) Abstract: A method of treatment or prophylaxis of stroke and other neurological diseases in a human which comprises ad-  
ministering an effective amount of a MAG antagonist or anti-MAG antibody including altered antibodies and functional fragments  
thereof.



**WO 02/062383 A2**

5

## Novel Method of Treatment

### Field of the Invention

The present invention relates to a method of treatment of neurological diseases and to antibodies for use in such method.

10

### Background of the Invention

Stroke is a major cause of death and disability in the Western World. There is no approved therapy for the treatment of stroke other than t-PA which has to be administered within 3h of onset following a CT scan to exclude haemorrhage. To date most

15 therapeutic agents directed towards the treatment of acute stroke (i.e. neuroprotection), have predominantly involved targeting glutamate receptors and their down stream signalling pathways known to be involved in acute cell death. However to date these strategies have proved unsuccessful in clinical trials and are often associated with dose-limiting side effects (Hill & Hachinski, The Lancet, 352 : (suppl III) 10-14 (1998)).

20 Therefore there is a need for novel approaches directed towards the amelioration of cell death following the cessation of blood flow.

Following the onset of stroke, some degree of spontaneous functional recovery is observed in many patients, suggesting that the brain has the (albeit limited) ability to repair and/or remodel following injury. Agents that have the potential to enhance this

25 recovery may therefore allow intervention to be made much later (potentially days) following the onset of cerebral ischaemia. Agents which are able to offer both acute neuroprotection and enhance functional recovery may provide significant advantages over current potential neuroprotective strategies.

The mechanisms underlying functional recovery are currently unknown. The

30 sprouting of injured or non-injured axons has been proposed as one possible mechanism. However, although *in vivo* studies have shown that treatment of spinal cord injury or stroke with neurotrophic factors results in enhanced functional recovery and a degree of axonal sprouting, these do not prove a direct link between the degree of axonal sprouting and extent of functional recovery (Jakeman, et al. 1998, Exp. Neurol. 154 : 170-184,

35 Kawamata et al. 1997, Proc Natl Acad. Sci. USA., 94:8179-8184, Ribotta, et al. 2000, J Neurosci. 20 : 5144-5152). Furthermore, axonal sprouting requires a viable neuron. In diseases such as stroke which is associated with extensive cell death, enhancement of

5 functional recovery offered by a given agent post stroke may therefore be through mechanisms other than axonal sprouting such as differentiation of endogenous stem cells, activation of redundant pathways, changes in receptor distribution or excitability of neurons or glia (Fawcett & Asher, 1999, Brain Res. Bulletin, 49 : 377-391, Horner & Gage, 2000, Nature 407 963-970).

10 The limited ability of the central nervous system (CNS) to repair following injury is thought in part to be due to molecules within the CNS environment that have an inhibitory effect on axonal sprouting (neurite outgrowth). CNS myelin is thought to contain inhibitory molecules (Schwab ME and Caroni P (1988) *J. Neurosci.* 8, 2381-2193). Two myelin proteins, myelin-associated glycoprotein (MAG) and Nogo have been  
15 cloned and identified as putative inhibitors of neurite outgrowth (Sato S. et al (1989) *Biochem. Biophys. Res. Comm.* 163, 1473-1480; McKerracher L et al (1994) *Neuron* 13, 805-811; Mukhopadhyay G et al (1994) *Neuron* 13, 757-767; Torigoe K and Lundborg G (1997) *Exp. Neurology* 150, 254-262; Schafer et al (1996) *Neuron* 16, 1107-1113; WO9522344; WO9701352; Prinjha R et al (2000) *Nature* 403, 383-384; Chen MS et al  
20 (2000) *Nature* 403, 434-439; GrandPre T et al (2000) *Nature* 403, 439-444; US005250414A; WO200005364A1; WO0031235).

Myelin-associated glycoprotein is a cell surface transmembrane molecule expressed on the surface of myelin consisting of five extracellular immunoglobulin domains, a single transmembrane domain and an intracellular domain. MAG expression  
25 is restricted to myelinating glia in the CNS and peripheral nervous system (PNS). MAG is thought to interact with neuronal receptor(s) which mediate effects on the neuronal cytoskeleton including neurofilament phosphorylation and inhibition of neurite outgrowth *in vitro*. Although antagonists of MAG have been postulated as useful for the promotion of axonal sprouting following injury (WO9522344, WO9701352 and WO9707810), these  
30 claims are not supported by *in vivo* data. Furthermore, the role of MAG as an inhibitor of axonal sprouting from CNS neurons *in vivo* is not proven (Li CM et al (1994) *Nature* 369, 747-750; Montag, D et al (1994) *Neuron* 13, 229-246; Lassmann H et al (1997) *GLIA* 19, 104-110; Li C et al (1998) *J. Neuro. Res.* 51, 210-217; Yin X et al (1998) *J. Neurosci.* 18, 1953-1962; Bartsch U et al (1995) *Neuron* 15 1375-1381; Li M et al (1996)  
35 46,404-414).

It has now been found that an anti-MAG monoclonal antibody, when administered either directly into the brain or intravenously following focal cerebral ischaemia in the rat

5 (a model of stroke), provides neuroprotection and enhances functional recovery.  
Therefore anti-MAG antibodies or MAG antagonists provide potential therapeutic agents  
for both acute neuroprotection as well as the promotion of functional recovery following  
stroke. Other agents that disrupt the interaction between MAG and its neuronal receptors  
(such as receptor antagonists or antibodies recognising the MAG receptor(s)) may also  
10 provide this therapeutic benefit.

The process of neurodegeneration underlies many neurological diseases including  
acute diseases such as stroke, traumatic brain injury and spinal cord injury as well as  
chronic diseases including Alzheimer's disease, fronto-temporal dementias (tauopathies),  
peripheral neuropathy, Parkinson's disease, Huntington's disease and multiple sclerosis.  
15 Anti-MAG mabs or MAG antagonists therefore may be useful in the treatment of these  
diseases, by both ameliorating the cell death associated with these disorders and  
promoting functional recovery.

#### **Brief Summary of the Invention**

20 In one aspect, the present invention provides a method of treatment or prophylaxis  
of stroke and other neurological diseases in a human which comprises administering to  
said human in need thereof an effective amount of a MAG antagonist or anti-MAG  
antibody, including altered antibodies or a functional fragment thereof.

In another aspect, the invention provides the use of a MAG antagonist or anti-  
25 MAG antibody, including altered antibodies or a functional fragment thereof in the  
preparation of a medicament for treatment or prophylaxis of stroke and other neurological  
diseases.

In a further aspect, the present invention provides a method of inhibiting  
neurodegeneration and/or promoting functional recovery in a human patient suffering, or  
30 at risk of developing, a stroke or other neurological disease which comprises  
administering to said human in need thereof an effective amount of a MAG antagonist or  
anti-MAG antibody, including altered antibodies or a functional fragment thereof.

In a yet further aspect, the invention provides the use of a MAG antagonist or  
anti-MAG antibody, including altered antibodies or a functional fragment thereof in the  
35 preparation of a medicament for inhibiting neurodegeneration and/or promoting  
functional recovery in a human patient suffering from, or at risk of developing, a stroke  
and other neurological disease.

5 In a further aspect, this invention provides altered anti-Mag antibodies and functional fragments thereof. The anti-Mag mABs may be useful in the methods of the invention.

The invention therefore provides an altered antibody or functional fragment thereof which comprises

- 10 a) an antibody light chain variable domain comprising a light chain of an acceptor monoclonal antibody having at least one of the CDRs of the antigen binding domain substituted by the CDRs of the antigen binding domain of the light chain of a non-human donor monoclonal antibody that specifically binds to MAG and/or
- 15 b) an antibody heavy chain variable domain comprising a heavy chain of an acceptor monoclonal antibody having at least one of the CDRs of the antigen binding domain substituted by the CDRs of the antigen binding domain of the heavy chain of a non-human donor monoclonal antibody that specifically binds to MAG.

20 In yet another aspect, the present invention provides a pharmaceutical composition which comprises one (or more) altered anti-MAG antibodies and a pharmaceutically acceptable carrier.

In a further aspect the invention provides an altered antibody or functional fragment thereof which comprises one or more of the following CDR's. The CDR's are identified as described by Kabat or Chothia and Lesk. (Kabat et al. (1991) Sequences of proteins of immunological interest; Fifth Edition; US Department of Health and Human Services; NIH publication No 91-3242, Chothia et al., (1989) Conformations of immunoglobulin hypervariable regions; Nature 342, p877-883). CDRs preferably are as defined by Kabat but following the principles of protein structure and folding as defined by Chothia and Lesk, it will be appreciated that additional residues may also be considered to be part of the antigen binding region and are thus encompassed by the present invention.

#### *Light chain CDRs*

35

<i>CDR</i>	<i>According to Kabat</i>	<i>according to Chothia&amp;Lesk</i>
------------	---------------------------	--------------------------------------

L1	KSSHSLVLYSSNQKNYLA	SHSLVLYSSNQKNY
L2	WASTRSE	WAS
L3	HQQLSSYT	HQQLSSY

5

**Heavy chain CDRs**

<b>CDR</b>	<b>according to Kabat</b>	<b>according to Chothia&amp;Lesk</b>
H1	NYNMN	GYTFTNYNM
H2	WINTYTGEPTYADDFKT	TYTG
H3	NPINYYGINYEGYVMDY	

10 In a further aspect, the present invention provides an altered antibody or functional fragment thereof which comprises a heavy chain variable domain which comprises one or more CDR's selected from CDRH1, CDRH2 and CDRH3 (as defined by Kabat and/or Chothia and Lesk) and/or a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3 (as defined by Kabat  
15 and/or Chothia and Lesk)

The invention further provides an altered anti-Mag antibody or functional fragment thereof which comprises:

- a) a heavy chain variable domain ( $V_H$ ) which comprises in sequence hypervariable regions CDRH1, CDRH2 and CDRH3,  
20 and /or
- b) a light chain variable domain ( $V_L$ ) which comprises in sequence hypervariable regions CDRL1, CDRL2 and CDRL3.

A further aspect of the invention provides a pharmaceutical composition  
25 comprising an altered anti-MAG antibody or functional fragment thereof together with a pharmaceutically acceptable diluent or carrier.

Other aspects and advantages of the present invention are described further in the detailed description and the preferred embodiments thereof.

## 5 **Description of the Figures**

Figure 1 shows the sequence of the light chain of the mouse anti-chick MAG antibody 1567 from Chemicon.

Figure 2 shows the sequence of the heavy chain of the mouse anti-chick MAG antibody 1567 from Chemicon.

10 Figure 3 .Nucleic acid sequence of the light chain variable region. CDR regions according to Kabat are highlighted

Figure 4. Nucleic acid sequence of the heavy chain variable region. CDR regions according to Kabat are highlighted.

Figure 5: Sequence of a mouse/human chimeric anti-MAG antibody heavy chain.

15 Figure 6: Sequence of a mouse/human chimeric anti-MAG antibody light chain.

## **Detailed Description of the Invention**

### **MAG Antagonist**

"MAG antagonist" refers to compounds which inhibit MAG function including its  
20 binding to neurones and inhibition of neurite outgrowth . Suitable assays for antagonists and examples of antagonists are disclosed in WO9522344, WO9701352 and WO9707810, including:

altered or mutated forms of MAG characterised by an altered biological activity;  
a sialic acid-bearing sugar;  
25 a modified derivative of sialic acid attached to a sugar;  
a sialic acid-bearing sugar attached to a protein or lipid carrier molecule;  
a modified sialic acid-bearing sugar attached to a protein or lipid carrier molecule;  
and

an enzyme that can alter or remove sialic acid residues having a Neu5Ac $\alpha$ 2-  
30 3Gal $\beta$ 1-3GalNAc structure, which mediate MAG binding to neuronal surfaces in the PNS or CNS.

An example of an altered form of MAG is a soluble chimeric protein which comprises extracellular Ig-like domains one to three or one to five of MAG linked to the Fc domain of a human immunoglobulin molecule such as IgG (MAG[d1-3]-Fc or  
35 MAG[d1-5]-Fc) as described in WO9701352.

5           An example of a free sialic acid-bearing sugar is sialo 2,3- $\alpha$ -lactose or 2,3-dideoxy sialic acid.

          An example of an enzyme is sialidase or sialyl transferase.

#### Anti-MAG Antibody

10           The antibody is preferably raised to human MAG and is preferably a monoclonal antibody (mAb) or an altered antibody, which is preferably humanised or reshaped.

          In a preferred aspect the mAb or altered antibody is class IgG.

          In a further preferred aspect the antibody is a neutralising antibody.

          The invention therefore further provides an altered anti-MAG antibody which  
15           comprises at least one CDR that specifically binds to MAG. Preferably the antibody is a humanised antibody.

          The invention therefore provides an altered antibody or functional fragment thereof which comprises

          c) an antibody light chain variable domain comprising a light chain of an  
20           acceptor monoclonal antibody having at least one of the CDRs of the antigen binding domain substituted by the CDRs of the antigen binding domain of the light chain of a non-human donor monoclonal antibody that specifically binds to MAG and/or

          d) an antibody heavy chain variable domain comprising a heavy chain of an  
25           acceptor monoclonal antibody having at least one of the CDRs of the antigen binding domain substituted by the CDRs of the antigen binding domain of the heavy chain of a non-human donor monoclonal antibody that specifically binds to MAG.

          In a more preferred aspect all three of the light chain and/or heavy chain CDRs of  
30           the acceptor antibody are replaced by the CDRs of the donor antibody. Preferably the acceptor antibody is human.

          "Neutralising" refers to substantial inhibition of MAG function including its binding to neurones and inhibition of neurite outgrowth.

          "Substantial inhibition" refers to 75%, more preferably 85%, most preferably 95%  
35           inhibition measured in *in vitro* tests.

          "Altered antibody" refers to a protein encoded by an altered immunoglobulin coding region, which may be obtained by expression in a selected host cell. Such altered



- 5 antibodies include engineered antibodies (e.g., chimeric, reshaped, humanized or vectored antibodies) or antibody fragments lacking all or part of an immunoglobulin constant region, e.g., Fv, Fab, or F(ab)<sub>2</sub> and the like.

"Altered immunoglobulin coding region" refers to a nucleic acid sequence encoding altered antibody. When the altered antibody is a CDR-grafted or humanized  
10 antibody, the sequences that encode the complementarity determining regions (CDRs) from a non-human immunoglobulin are inserted into a first immunoglobulin partner comprising human variable framework sequences. Optionally, the first immunoglobulin partner is operatively linked to a second immunoglobulin partner.

"First immunoglobulin partner" refers to a nucleic acid sequence encoding a  
15 human framework or human immunoglobulin variable region in which the native (or naturally-occurring) CDR-encoding regions are replaced by the CDR-encoding regions of a donor antibody. The human variable region can be an immunoglobulin heavy chain, a light chain (or both chains), an analog or functional fragments thereof. Such CDR regions, located within the variable region of antibodies (immunoglobulins) can be  
20 determined by known methods in the art. For example Kabat et al. (Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987)) disclose rules for locating CDRs. In addition, computer programs are known which are useful for identifying CDR regions/structures.

25 "Second immunoglobulin partner" refers to another nucleotide sequence encoding a protein or peptide to which the first immunoglobulin partner is fused in frame or by means of an optional conventional linker sequence (i.e., operatively linked). Preferably it is an immunoglobulin gene. The second immunoglobulin partner may include a nucleic acid sequence encoding the entire constant region for the same (i.e., homologous - the  
30 first and second altered antibodies are derived from the same source) or an additional (i.e., heterologous) antibody of interest. It may be an immunoglobulin heavy chain or light chain (or both chains as part of a single polypeptide). The second immunoglobulin partner is not limited to a particular immunoglobulin class or isotype. In addition, the second immunoglobulin partner may comprise part of an immunoglobulin constant  
35 region, such as found in a Fab, or F(ab)<sub>2</sub> (i.e., a discrete part of an appropriate human constant region or framework region). Such second immunoglobulin partner may also

5 comprise a sequence encoding an integral membrane protein exposed on the outer surface of a host cell, e.g., as part of a phage display library, or a sequence encoding a protein for analytical or diagnostic detection, e.g., horseradish peroxidase,  $\beta$ -galactosidase, etc.

The terms Fv, Fc, Fd, Fab, or F(ab)<sub>2</sub> are used with their standard meanings (see, e.g., Harlow et al., Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory,  
10 (1988)).

As used herein, an "engineered antibody" describes a type of altered antibody, i.e., a full-length synthetic antibody (e.g., a chimeric, reshaped or humanized antibody as opposed to an antibody fragment) in which a portion of the light and/or heavy chain variable domains of a selected acceptor antibody are replaced by analogous parts from  
15 one or more donor antibodies which have specificity for the selected epitope. For example, such molecules may include antibodies characterized by a humanized heavy chain associated with an unmodified light chain (or chimeric light chain), or vice versa. Engineered antibodies may also be characterized by alteration of the nucleic acid sequences encoding the acceptor antibody light and/or heavy variable domain framework  
20 regions in order to retain donor antibody binding specificity. These antibodies can comprise replacement of one or more CDRs (preferably all) from the acceptor antibody with CDRs from a donor antibody described herein.

A "chimeric antibody" refers to a type of engineered antibody which contains a naturally-occurring variable region (light chain and heavy chains) derived from a donor  
25 antibody in association with light and heavy chain constant regions derived from an acceptor antibody.

A "humanized antibody" refers to a type of engineered antibody having its CDRs derived from a non-human donor immunoglobulin, the remaining immunoglobulin-derived parts of the molecule being derived from one (or more) human  
30 immunoglobulin(s). In addition, framework support residues may be altered to preserve binding affinity (see, e.g., Queen et al., Proc. Natl Acad Sci USA, 86:10029-10032 (1989), Hodgson et al., Bio/Technology, 9:421 (1991)).

"Reshaped human antibody" refers to an altered antibody in which minimally at least one CDR from a first human monoclonal donor antibody is substituted for a CDR in  
35 a second human acceptor antibody. Preferably all six CDRs are replaced. More preferably an entire antigen combining region (e.g., Fv, Fab or F(ab')<sub>2</sub>) from a first human donor monoclonal antibody is substituted for the corresponding region in a second

5 human acceptor monoclonal antibody. Most preferably the Fab region from a first human donor is operatively linked to the appropriate constant regions of a second human acceptor antibody to form a full length monoclonal antibody.

A "vectored antibody" refers to an antibody to which an agent has been attached to improve transport through the blood brain barrier (BBB). The attachment may be  
10 chemical or alternatively the moiety can be engineered into the antibody. One example is to make a chimera with an antibody directed towards a brain capillary endothelial cell receptor eg an anti-insulin receptor antibody or anti-transferrin receptor antibody (Saito et al (1995) *Proc. Natl. Acad. Sci. USA* **92** 10227-31; Pardridge et al (1995) *Pharm. Res.* **12** 807-816; Broadwell et al (1996) *Exp. Neurol.* **142** 47-65; Bickel et al (1993) *Proc Natl.*  
15 *Acad. Sci. USA* **90**, 2618-2622; Friden et al (1996) *J. Pharm. Exp. Ther.* **278** 1491-1498, US5182107, US5154924, US5833988, US5527527). Once bound to the receptor, both components of the bispecific antibody pass across the BBB by the process of transcytosis. Alternatively the agent may be a ligand which binds such cell surface receptors eg  
20 insulin, transferrin or low density lipoprotein (Descamps et al (1996) *Am. J. Physiol.* **270** H1149-H1158; Duffy et al (1987) *Brain Res.* **420** 32-38; Dehouck et al (1997) *J. Cell Biol.* **1997** 877-889). Naturally occurring peptides such as penetratin and SynB1 and SynB3 which are known to improve transport across the BBB can also be used (Rouselle et al (2000) *Mol. Pharm.* **57**, 679-686 and Rouselle et al (2001) *Journal of Pharmacology and Experimental Therapeutics* **296**, 124-131).

25 The term "donor antibody" refers to an antibody (monoclonal, or recombinant) which contributes the nucleic acid sequences of its variable regions, CDRs, or other functional fragments or analogs thereof to a first immunoglobulin partner, so as to provide the altered immunoglobulin coding region and resulting expressed altered antibody with the antigenic specificity and neutralizing activity characteristic of the donor  
30 antibody.

The term "acceptor antibody" refers to an antibody (monoclonal, or recombinant) heterologous to the donor antibody, which contributes all (or any portion, but preferably all) of the nucleic acid sequences encoding its heavy and/or light chain framework regions and/or its heavy and/or light chain constant regions to the first immunoglobulin  
35 partner. Preferably a human antibody is the acceptor antibody.

"CDRs" are defined as the complementarity determining region amino acid sequences of an antibody which are the hypervariable regions of immunoglobulin heavy and light

5 chains. See, e.g., Kabat et al., Sequences of Proteins of Immunological Interest, 4th Ed., U.S. Department of Health and Human Services, National Institutes of Health (1987). There are three heavy chain and three light chain CDRs (or CDR regions) in the variable portion of an immunoglobulin. Thus, "CDRs" as used herein refers to all three heavy chain CDRs, or all three light chain CDRs (or both all heavy and all light chain CDRs, if  
10 appropriate). ). The structure and protein folding of the antibody may mean that other residues are considered part of the antigen binding region and would be understood to be so by a skilled person. See for example Chothia et al., (1989) Conformations of immunoglobulin hypervariable regions; Nature 342, p877-883.

CDRs provide the majority of contact residues for the binding of the antibody to  
15 the antigen or epitope. CDRs of interest in this invention are derived from donor antibody variable heavy and light chain sequences, and include analogs of the naturally occurring CDRs, which analogs also share or retain the same antigen binding specificity and/or neutralizing ability as the donor antibody from which they were derived.

A "functional fragment" is a partial heavy or light chain variable sequence (e.g.,  
20 minor deletions at the amino or carboxy terminus of the immunoglobulin variable region) which retains the same antigen binding specificity and/or neutralizing ability as the antibody from which the fragment was derived.

An "analog" is an amino acid sequence modified by at least one amino acid, wherein said modification can be chemical or a substitution or a rearrangement of a few  
25 amino acids (i.e., no more than 10), which modification permits the amino acid sequence to retain the biological characteristics, e.g., antigen specificity and high affinity, of the unmodified sequence. For example, (silent) mutations can be constructed, via substitutions, when certain endonuclease restriction sites are created within or surrounding CDR-encoding regions. . The present invention contemplates the use of  
30 analogs of the antibody of the invention. It is well known that minor changes in amino acid or nucleic acid sequences may lead eg to an allelic form of the original protein which retains substantially similar properties. Thus analogs of the antibody of the invention includes those in which the CDRs in the hypervariable region of the heavy and light chains are at least 80% homologous, preferably at least 90 % homologous and more  
35 preferably at least 95 % homologous to the CDRs as defined above as CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3 and retain MAG neutralising activity. Amino acid sequences are at least 80% homologous if they have 80% identical amino acid

5 residues in a like position when the sequences are aligned optimally, gaps or insertions being counted as non-identical residues.

Analogs may also arise as allelic variations. An "allelic variation or modification" is an alteration in the nucleic acid sequence. Such variations or modifications may be due to degeneracy in the genetic code or may be deliberately engineered to provide desired  
10 characteristics. These variations or modifications may or may not result in alterations in any encoded amino acid sequence.

The term "effector agents" refers to non-protein carrier molecules to which the altered antibodies, and/or natural or synthetic light or heavy chains of the donor antibody or other fragments of the donor antibody may be associated by conventional means. Such  
15 non-protein carriers can include conventional carriers used in the diagnostic field, e.g., polystyrene or other plastic beads, polysaccharides, e.g., as used in the BIAcore [Pharmacia] system, or other non-protein substances useful in the medical field and safe for administration to humans and animals. Other effector agents may include a macrocycle, for chelating a heavy metal atom, or radioisotopes. Such effector agents may  
20 also be useful to increase the half-life of the altered antibodies, e.g., polyethylene glycol.

A neutralising antibody specific for MAG has been described (Poltorak et al (1987) *Journal of Cell Biology* **105**,1893-1899, DeBellard et al (1996) *Mol. Cell. Neurosci.* **7**, 89-101; Tang et al (1997) *Mol. Cell. Neurosci.* **9**, 333-346; Torigoe K and Lundborg G (1997) *Exp. Neurology* **150**, 254-262) and is commercially available  
25 (MAB1567 (Chemicon)).

This antibody has been sequenced and thus in a preferred aspect the invention provides an altered anti-MAG antibody or functional fragment thereof which comprises: an altered antibody or functional fragment thereof which comprises one or more of the following CDR's. The CDR's are identified as described by Kabat or Chothia and Lesk.  
30 (Kabat et al. (1991) Sequences of proteins of immunological interest; Fifth Edition; US Department of Health and Human Services; NIH publication No 91-3242, Chothia et al., (1989) Conformations of immunoglobulin hypervariable regions; Nature 342, p877-883). Both are encompassed by the present invention

35

#### ***Light chain CDRs***

<b>CDR</b>	<b><i>according to Kabat</i></b>	<b><i>according to Chothia&amp;Lesk</i></b>
L1	KSSHSVLYSSNQKNYLA	SHSVLYSSNQKNY
L2	WASTRSE	WAS
L3	HQQLSSYT	HQQLSSY

5

***Heavy chain CDRs***

<b>CDR</b>	<b><i>according to Kabat</i></b>	<b><i>according to Chothia&amp;Lesk</i></b>
H1	NYNMN	GYTFTNYNM
H2	WINTYTGEPTYADDFKT	TYTG
H3	NPINYYGINYEGYVMDY	

10 In a further aspect, the present invention provides an altered antibody or functional fragment thereof which comprises a heavy chain variable domain which comprises one or more CDR's selected from CDRH1, CDRH2 and CDRH3 (as defined by Kabat and/or Chothia and Lesk) and/or a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3 (as defined by Kabat and/or Chothia and Lesk)

15

The invention further provides an altered anti-Mag antibody or functional fragment thereof which comprises:

- c) a heavy chain variable domain ( $V_H$ ) which comprises in sequence hypervariable regions CDRH1, CDRH2 and CDRH3,
- 20 and /or
- d) a light chain variable domain ( $V_L$ ) which comprises in sequence hypervariable regions CDRL1, CDRL2 and CDRL3.

20

In a further aspect, the invention provides polynucleotides encoding CDR1H, CDR2H, CDR3H, CDR1L, CDR2L and CDR3L. Preferred polynucleotide sequences are underlined in Figures 4 and 5.

25

In a further aspect of the invention, there is provided a polynucleotide encoding a light chain variable region of an altered anti-MAG antibody including at least one CDR

5 selected from CDRL1, CDRL2 and CDRL3, more preferably including all 3 CDRs in sequence.

In a further aspect of the invention, there is provided a polynucleotide encoding a heavy chain variable region of an altered anti-MAG antibody including at least one CDR selected from CDRH1, CDRH2 and CDRH3, more preferably including all 3 CDRs in  
10 sequence.

A further aspect of the invention provides a pharmaceutical composition comprising an altered anti-MAG antibody or functional fragment thereof together with a pharmaceutically acceptable diluent or carrier.

The altered antibody is preferably monoclonal, preferably humanised.

15 Alternatively, one can construct antibodies, altered antibodies and fragments, by immunizing a non-human species (for example, bovine, ovine, monkey, chicken, rodent (e.g., murine and rat), etc.) to generate a desirable immunoglobulin upon presentation with native MAG from any species against which antibodies cross reactive with human MAG can be generated, eg human or chicken. . Conventional hybridoma techniques are  
20 employed to provide a hybridoma cell line secreting a non-human mAb to MAG. Such hybridomas are then screened for binding using MAG coated to 384- or 96-well plates, with biotinylated MAG bound to a streptavidin coated plate. or in a homogenous europium-APC linked immunoassay using biotinylated MAG.

A native human antibody can be produced in a human antibody mouse such as the  
25 "Xenomouse" (Abgenix) where the mouse immunoglobulin genes have been removed and genes encoding the human immunoglobulins have been inserted into the mouse chromosome. The mice are immunised as normal and develop an antibody response that is derived from the human genes. Thus the mouse produces human antibodies obviating the need to humanize the after selection of positive hybridomas. (See Green L.L., *J Immunol Methods* 1999 Dec 10;231(1-2):11-23)  
30

The present invention also includes the use of Fab fragments or F(ab')<sub>2</sub> fragments derived from mAbs directed against MAG. These fragments are useful as agents protective *in vivo*. A Fab fragment contains the entire light chain and amino terminal portion of the heavy chain; and an F(ab')<sub>2</sub> fragment is the fragment formed by two Fab  
35 fragments bound by disulfide bonds. Fab fragments and F(ab')<sub>2</sub> fragments can be obtained by conventional means, e.g., cleavage of mAb with the appropriate proteolytic

5 enzymes, papain and/or pepsin, or by recombinant methods. The Fab and F(ab')<sub>2</sub> fragments are useful themselves as therapeutic or prophylactic, and as donors of sequences including the variable regions and CDR sequences useful in the formation of recombinant or humanized antibodies as described herein.

The Fab and F(ab')<sub>2</sub> fragments can also be constructed via a combinatorial phage  
10 library (see, e.g., Winter et al., Ann. Rev. Immunol., 12:433-455 (1994)) or via immunoglobulin chain shuffling (see, e.g., Marks et al., Bio/Technology, 10:779-783 (1992), which are both hereby incorporated by reference in their entirety.

Thus human antibody fragments (Fv, scFv, Fab) specific for MAG can be isolated using human antibody fragment phage display libraries. A library of bacteriophage  
15 particles, which display the human antibody fragment proteins, are panned against the MAG protein. Those phage displaying antibody fragments that bind the MAG are retained from the library and clonally amplified. The human antibody genes are then excised from the specific bacteriophage and inserted into human IgG expression constructs containing the human IgG constant regions to form the intact human IgG  
20 molecule with the variable regions from the isolated bacteriophage specific for MAG.

The donor antibodies may contribute sequences, such as variable heavy and/or light chain peptide sequences, framework sequences, CDR sequences, functional fragments, and analogs thereof, and the nucleic acid sequences encoding them, useful in  
25 designing and obtaining various altered antibodies which are characterized by the antigen binding specificity of the donor antibody.

Taking into account the degeneracy of the genetic code, various coding sequences may be constructed which encode the variable heavy and light chain amino acid sequences, and CDR sequences as well as functional fragments and analogs thereof which share the antigen specificity of the donor antibody. Isolated nucleic acid  
30 sequences, or fragments thereof, encoding the variable chain peptide sequences or CDRs can be used to produce altered antibodies, e.g., chimeric or humanized antibodies, or other engineered antibodies when operatively combined with a second immunoglobulin partner.

Altered immunoglobulin molecules can encode altered antibodies which include  
35 engineered antibodies such as chimeric antibodies and humanized antibodies. A desired altered immunoglobulin coding region contains CDR-encoding regions that encode peptides having the antigen specificity of an anti-MAG antibody, preferably a high



5 affinity antibody, inserted into a first immunoglobulin partner (a human framework or human immunoglobulin variable region).

Preferably, the first immunoglobulin partner is operatively linked to a second immunoglobulin partner. The second immunoglobulin partner is defined above, and may include a sequence encoding a second antibody region of interest, for example an Fc region. Second immunoglobulin partners may also include sequences encoding another immunoglobulin to which the light or heavy chain constant region is fused in frame or by means of a linker sequence. Engineered antibodies directed against functional fragments or analogs of MAG may be designed to elicit enhanced binding.

10 The second immunoglobulin partner may also be associated with effector agents as defined above, including non-protein carrier molecules, to which the second immunoglobulin partner may be operatively linked by conventional means.

Fusion or linkage between the second immunoglobulin partners, e.g., antibody sequences, and the effector agent may be by any suitable means, e.g., by conventional covalent or ionic bonds, protein fusions, or hetero-bifunctional cross-linkers, e.g., carbodiimide, glutaraldehyde, and the like. Such techniques are known in the art and readily described in conventional chemistry and biochemistry texts.

20 Additionally, conventional linker sequences which simply provide for a desired amount of space between the second immunoglobulin partner and the effector agent may also be constructed into the altered immunoglobulin coding region. The design of such linkers is well known to those of skill in the art.

In still a further embodiment, the antibody of the invention may have attached to it an additional agent. For example, the procedure of recombinant DNA technology may be used to produce an engineered antibody of the invention in which the Fc fragment or CH2-CH3 domain of a complete antibody molecule has been replaced by an enzyme or other detectable molecule (i.e., a polypeptide effector or reporter molecule).

30 The second immunoglobulin partner may also be operatively linked to a non-immunoglobulin peptide, protein or fragment thereof heterologous to the CDR-containing sequence having the antigen specificity of anti-MAG antibody. The resulting protein may exhibit both anti-MAG antigen specificity and characteristics of the non-immunoglobulin upon expression. That fusion partner characteristic may be, e.g., a functional characteristic such as another binding or receptor domain, or a therapeutic

5 characteristic if the fusion partner is itself a therapeutic protein, or additional antigenic characteristics.

Another desirable protein of this invention may comprise a complete antibody molecule, having full length heavy and light chains, or any discrete fragment thereof, such as the Fab or F(ab')<sub>2</sub> fragments, a heavy chain dimer, or any minimal recombinant  
10 fragments thereof such as an F<sub>v</sub> or a single-chain antibody (SCA) or any other molecule with the same specificity as the selected donor mAb. Such protein may be used in the form of an altered antibody, or may be used in its unfused form.

Whenever the second immunoglobulin partner is derived from an antibody different from the donor antibody, e.g., any isotype or class of immunoglobulin  
15 framework or constant regions, an engineered antibody results. Engineered antibodies can comprise immunoglobulin (Ig) constant regions and variable framework regions from one source, e.g., the acceptor antibody, and one or more (preferably all) CDRs from the donor antibody. In addition, alterations, e.g., deletions, substitutions, or additions, of the acceptor mAb light and/or heavy variable domain framework region at the nucleic acid or  
20 amino acid levels, or the donor CDR regions may be made in order to retain donor antibody antigen binding specificity.

Such engineered antibodies are designed to employ one (or both) of the variable heavy and/or light chains of the anti-MAG mAb or one or more of the heavy or light chain CDRs. The engineered antibodies may be neutralising, as above defined.

25 Such engineered antibodies may include a humanized antibody containing the framework regions of a selected human immunoglobulin or subtype, or a chimeric antibody containing the human heavy and light chain constant regions fused to the anti-MAG antibody functional fragments. A suitable human (or other animal) acceptor antibody may be one selected from a conventional database, e.g., the KABAT® database,  
30 Los Alamos database, and Swiss Protein database, by homology to the nucleotide and amino acid sequences of the donor antibody. A human antibody characterized by a homology to the framework regions of the donor antibody (on an amino acid basis) may be suitable to provide a heavy chain constant region and/or a heavy chain variable framework region for insertion of the donor CDRs. A suitable acceptor antibody capable  
35 of donating light chain constant or variable framework regions may be selected in a similar manner. It should be noted that the acceptor antibody heavy and light chains are not required to originate from the same acceptor antibody.

5 Desirably the heterologous framework and constant regions are selected from human immunoglobulin classes and isotypes, such as IgG (subtypes 1 through 4), IgM, IgA, and IgE. However, the acceptor antibody need not comprise only human immunoglobulin protein sequences. For instance a gene may be constructed in which a DNA sequence encoding part of a human immunoglobulin chain is fused to a DNA  
10 sequence encoding a non-immunoglobulin amino acid sequence such as a polypeptide effector or reporter molecule.

Preferably, in a humanized antibody, the variable domains in both human heavy and light chains have been engineered by one or more CDR replacements. It is possible to use all six CDRs, or various combinations of less than the six CDRs. Preferably all six  
15 CDRs are replaced. It is possible to replace the CDRs only in the human heavy chain, using as light chain the unmodified light chain from the human acceptor antibody. Alternatively, a compatible light chain may be selected from another human antibody by recourse to the conventional antibody databases. The remainder of the engineered antibody may be derived from any suitable acceptor human immunoglobulin.

20 The engineered humanized antibody thus preferably has the structure of a natural human antibody or a fragment thereof, and possesses the combination of properties required for effective therapeutic use.

It will be understood by those skilled in the art that an engineered antibody may be further modified by changes in variable domain amino acids without necessarily  
25 affecting the specificity and high affinity of the donor antibody (i.e., an analog). It is anticipated that heavy and light chain amino acids may be substituted by other amino acids either in the variable domain frameworks or CDRs or both.

In addition, the constant region may be altered to enhance or decrease selective properties of the molecules of the instant invention. For example, dimerization, binding  
30 to Fc receptors, or the ability to bind and activate complement (see, e.g., Angal et al., Mol. Immunol, 30:105-108 (1993), Xu et al., J. Biol. Chem, 269:3469-3474 (1994), Winter et al., EP 307,434-B).

An altered antibody which is a chimeric antibody differs from the humanized antibodies described above by providing the entire non-human donor antibody heavy  
35 chain and light chain variable regions, including framework regions, in association with human immunoglobulin constant regions for both chains.

5 Preferably, the variable light and/or heavy chain sequences and the CDRs of suitable donor mAbs, and their encoding nucleic acid sequences, are utilized in the construction of altered antibodies, preferably humanized antibodies, of this invention, by the following process. The same or similar techniques may also be employed to generate other embodiments of this invention.

10 A hybridoma producing a selected donor mAb is conventionally cloned, and the DNA of its heavy and light chain variable regions obtained by techniques known to one of skill in the art, e.g., the techniques described in Sambrook *et al.*, (Molecular Cloning (A Laboratory Manual)), 2nd edition, Cold Spring Harbor Laboratory (1989)). The variable heavy and light regions containing at least the CDR-encoding regions and those  
15 portions of the acceptor mAb light and/or heavy variable domain framework regions required in order to retain donor mAb binding specificity, as well as the remaining immunoglobulin-derived parts of the antibody chain derived from a human immunoglobulin are obtained using polynucleotide primers and reverse transcriptase. The CDR-encoding regions are identified using a known database and by comparison to  
20 other antibodies.

A mouse/human chimeric antibody may then be prepared and assayed for binding ability. Such a chimeric antibody contains the entire non-human donor antibody V<sub>H</sub> and V<sub>L</sub> regions, in association with human Ig constant regions for both chains.

Homologous framework regions of a heavy chain variable region from a human  
25 antibody may be identified using computerized databases, e.g., KABAT®, and a human antibody having homology to the donor antibody will be selected as the acceptor antibody. A suitable light chain variable framework region can be designed in a similar manner.

A humanized antibody may be derived from the chimeric antibody, or preferably,  
30 made synthetically by inserting the donor mAb CDR-encoding regions from the heavy and light chains appropriately within the selected heavy and light chain framework. Alternatively, a humanized antibody can be made using standard mutagenesis techniques. Thus, the resulting humanized antibody contains human framework regions and donor mAb CDR-encoding regions. There may be subsequent manipulation of framework  
35 residues. The resulting humanized antibody can be expressed in recombinant host cells, e.g., COS, CHO or myeloma cells.

5           A conventional expression vector or recombinant plasmid is produced by placing these coding sequences for the antibody in operative association with conventional regulatory control sequences capable of controlling the replication and expression in, and/or secretion from, a host cell. Regulatory sequences include promoter sequences, e.g., CMV promoter, and signal sequences, which can be derived from other known  
10           antibodies. Similarly, a second expression vector can be produced having a DNA sequence which encodes a complementary antibody light or heavy chain. Preferably this second expression vector is identical to the first except insofar as the coding sequences and selectable markers are concerned, so to ensure as far as possible that each polypeptide chain is functionally expressed. Alternatively, the heavy and light chain  
15           coding sequences for the altered antibody may reside on a single vector.

          A selected host cell is co-transfected by conventional techniques with both the first and second vectors (or simply transfected by a single vector) to create the transfected host cell of the invention comprising both the recombinant or synthetic light and heavy chains. The transfected cell is then cultured by conventional techniques to produce the  
20           engineered antibody of the invention. The humanized antibody which includes the association of both the recombinant heavy chain and/or light chain is screened from culture by appropriate assay, such as ELISA or RIA. Similar conventional techniques may be employed to construct other altered antibodies and molecules.

          Suitable vectors for the cloning and subcloning steps employed in the methods and  
25           construction of the compositions of this invention may be selected by one of skill in the art. For example, the conventional pUC series of cloning vectors, may be used. One vector, pUC19, is commercially available from supply houses, such as Amersham (Buckinghamshire, United Kingdom) or Pharmacia (Uppsala, Sweden). Additionally, any vector which is capable of replicating readily, has an abundance of cloning sites and  
30           selectable genes (e.g., antibiotic resistance), and is easily manipulated may be used for cloning. Thus, the selection of the cloning vector is not a limiting factor in this invention.

          Similarly, the vectors employed for expression of the antibodies may be selected by one of skill in the art from any conventional vector. The vectors also contain selected regulatory sequences (such as CMV promoters) which direct the replication and  
35           expression of heterologous DNA sequences in selected host cells. These vectors contain the above described DNA sequences which code for the antibody or altered immunoglobulin coding region. In addition, the vectors may incorporate the selected

5 immunoglobulin sequences modified by the insertion of desirable restriction sites for ready manipulation.

The expression vectors may also be characterized by genes suitable for amplifying expression of the heterologous DNA sequences, e.g., the mammalian dihydrofolate reductase gene (DHFR). Other preferable vector sequences include a poly A signal  
10 sequence, such as from bovine growth hormone (BGH) and the betaglobin promoter sequence (betaglopro). The expression vectors useful herein may be synthesized by techniques well known to those skilled in this art.

The components of such vectors, e.g. replicons, selection genes, enhancers, promoters, signal sequences and the like, may be obtained from commercial or natural  
15 sources or synthesized by known procedures for use in directing the expression and/or secretion of the product of the recombinant DNA in a selected host. Other appropriate expression vectors of which numerous types are known in the art for mammalian, bacterial, insect, yeast, and fungal expression may also be selected for this purpose.

The present invention also encompasses a cell line transfected with a recombinant  
20 plasmid containing the coding sequences of the antibodies or altered immunoglobulin molecules thereof. Host cells useful for the cloning and other manipulations of these cloning vectors are also conventional. However, most desirably, cells from various strains of *E. coli* are used for replication of the cloning vectors and other steps in the construction of altered antibodies of this invention.

25 Suitable host cells or cell lines for the expression of the antibody of the invention are preferably mammalian cells such as NS0, Sp2/0, CHO, COS, a fibroblast cell (e.g., 3T3), and myeloid cells, and more preferably a CHO or a myeloid cell. Human cells may be used, thus enabling the molecule to be modified with human glycosylation patterns. Alternatively, other eukaryotic cell lines may be employed. The selection of suitable  
30 mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Sambrook *et al.*, cited above.

Bacterial cells may prove useful as host cells suitable for the expression of the recombinant Fabs of the present invention (see, e.g., Plückthun, A., Immunol. Rev.,  
35 130:151-188 (1992)). However, due to the tendency of proteins expressed in bacterial cells to be in an unfolded or improperly folded form or in a non-glycosylated form, any recombinant Fab produced in a bacterial cell would have to be screened for retention of

5 antigen binding ability. If the molecule expressed by the bacterial cell was produced in a properly folded form, that bacterial cell would be a desirable host. For example, various strains of *E. coli* used for expression are well-known as host cells in the field of biotechnology. Various strains of *B. subtilis*, *Streptomyces*, other bacilli and the like may also be employed in this method.

10 Where desired, strains of yeast cells known to those skilled in the art are also available as host cells, as well as insect cells, e.g. *Drosophila* and *Lepidoptera* and viral expression systems. See, e.g. Miller *et al.*, Genetic Engineering, 8:277-298, Plenum Press (1986) and references cited therein.

The general methods by which the vectors may be constructed, the transfection  
15 methods required to produce the host cells of the invention, and culture methods necessary to produce the altered antibody of the invention from such host cell are all conventional techniques. Likewise, once produced, the antibodies of the invention may be purified from the cell culture contents according to standard procedures of the art, including ammonium sulfate precipitation, affinity columns, column chromatography, gel  
20 electrophoresis and the like. Such techniques are within the skill of the art and do not limit this invention.

Yet another method of expression of the antibodies may utilize expression in a transgenic animal, such as described in U. S. Patent No. 4,873,316. This relates to an expression system using the animal's casein promoter which when transgenically  
25 incorporated into a mammal permits the female to produce the desired recombinant protein in its milk.

Once expressed by the desired method, the antibody is then examined for *in vitro* activity by use of an appropriate assay. Presently conventional ELISA assay formats are employed to assess qualitative and quantitative binding of the antibody to MAG.  
30 Additionally, other *in vitro* assays may also be used to verify neutralizing efficacy prior to subsequent human clinical studies performed to evaluate the persistence of the antibody in the body despite the usual clearance mechanisms.

The therapeutic agents of this invention may be administered as a prophylactic or post injury, or as otherwise needed. The dose and duration of treatment relates to the  
35 relative duration of the molecules of the present invention in the human circulation, and can be adjusted by one of skill in the art depending upon the condition being treated and the general health of the patient.

5           The mode of administration of the therapeutic agent of the invention may be any suitable route which delivers the agent to the host. The antagonists and antibodies, and pharmaceutical compositions of the invention are particularly useful for parenteral administration, i.e., subcutaneously, intramuscularly, intravenously, or intranasally.

          Therapeutic agents of the invention may be prepared as pharmaceutical  
10       compositions containing an effective amount of the antagonist or antibody of the invention as an active ingredient in a pharmaceutically acceptable carrier. In the prophylactic agent of the invention, an aqueous suspension or solution containing the engineered antibody, preferably buffered at physiological pH, in a form ready for injection is preferred. The compositions for parenteral administration will commonly  
15       comprise a solution of the antagonist or antibody of the invention or a cocktail thereof dissolved in an pharmaceutically acceptable carrier, preferably an aqueous carrier. A variety of aqueous carriers may be employed, e.g., 0.9% saline, 0.3% glycine, and the like. These solutions are sterile and generally free of particulate matter. These solutions may be sterilized by conventional, well known sterilization techniques (e.g., filtration).  
20       The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, etc. The concentration of the antagonist or antibody of the invention in such pharmaceutical formulation can vary widely, i.e., from less than about 0.5%, usually at or at least about 1% to as much as 15 or 20% by weight and will be selected primarily based  
25       on fluid volumes, viscosities, etc., according to the particular mode of administration selected.

          Thus, a pharmaceutical composition of the invention for intramuscular injection could be prepared to contain 1 mL sterile buffered water, and between about 1 ng to about 100 mg, e.g. about 50 ng to about 30 mg or more preferably, about 5 mg to about  
30       25 mg, of an antagonist or antibody of the invention. Similarly, a pharmaceutical composition of the invention for intravenous infusion could be made up to contain about 250 ml of sterile Ringer's solution, and about 1 to about 30 and preferably 5 mg to about 25 mg of an engineered antibody of the invention. Actual methods for preparing parenterally administrable compositions are well known or will be apparent to those  
35       skilled in the art and are described in more detail in, for example, Remington's Pharmaceutical Science, 15th ed., Mack Publishing Company, Easton, Pennsylvania.



5           It is preferred that the therapeutic agent of the invention, when in a pharmaceutical preparation, be present in unit dose forms. The appropriate therapeutically effective dose can be determined readily by those of skill in the art. To effectively treat stroke and other neurological diseases in a human, one dose of up to 700 mg per 70 kg body weight of an antagonist or antibody of this invention should be  
10 administered parenterally, preferably *i.v.* or *i.m.* (intramuscularly). Such dose may, if necessary, be repeated at appropriate time intervals selected as appropriate by a physician.

          The antibodies described herein can be lyophilized for storage and reconstituted in a suitable carrier prior to use. This technique has been shown to be effective with  
15 conventional immunoglobulins and art-known lyophilization and reconstitution techniques can be employed.

          In another aspect, the invention provides a pharmaceutical composition comprising a MAG antagonist or anti-MAG antibody, including altered antibodies or a functional fragment thereof and a pharmaceutically acceptable carrier for treatment or  
20 prophylaxis of stroke and other neurological diseases.

          In a yet further aspect, the invention provides a pharmaceutical composition comprising a MAG antagonist or anti-MAG antibody, including altered antibodies or a functional fragment thereof and a pharmaceutically acceptable carrier for inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering, or  
25 at risk of developing, a stroke or other neurological disease.

          The following examples illustrate the invention.

## **Materials and Methods**

### **30   *Anti-MAG monoclonal antibody***

          Anti-MAG monoclonal antibody was mouse anti-chick MAG antibody MAB 1567 obtained from Chemicon. The antibody has the following characteristics:

          Antigen: myelin-associated glycoprotein (human, mouse, rat, bovine, chick, frog)

          Isotype: IgG1

35           Neutralising ability: see DeBellard et al (1996) *Mol. Cell. Neurosci.* 7, 89-101; Tang et al (1997) *Mol. Cell. Neurosci.* 9, 333-346; Torigoe K and Lundborg G (1997) *Exp. Neurology* 150, 254-262.

5 Control IgG1 mab was purchased from R+D Systems.

This antibody was sequenced and the results are shown in Figures 1 and 2. Figure 1 shows the sequence of the variable chain (SEQ ID No: 7) and constant chain (SEQ ID No: 8) of the light chain. Figure 2 shows the sequence of the variable chain (SEQ ID No 9) and constant chain (SEQ ID No 10) of the heavy chain.

10

*Intra-cerebral ventricular cannulation (for study 1 only)*

Under halothane anaesthesia intra-cerebral ventricular (i.c.v.) cannulae were positioned in the left lateral cerebral ventricle (coordinates :1.6mm from the midline, 0.8mm caudal from bregma, 4.1mm from skull surface, incisor bar -3.2mm below zero according to Paxinos and Watson, 1986) All rats were singly housed to avoid damage to the guide or dummy cannula. 7 days following surgery, correct cannula placement was verified by an intense drinking response to Angiotensin II (100ng, Simpson, et al. 1978). Nine days later, animals underwent cerebral ischaemia.

20

*Transient Focal Cerebral Ischaemia*

Transient (90 min) focal cerebral ischaemia was induced in male Sprague Dawley rats, each weighing between 300-350g. The animals were initially anaesthetised with a mixture of 5% halothane, 60% nitrous oxide and 30% oxygen, placed on a facemask and anaesthesia subsequently maintained at 1.5% halothane. Middle cerebral artery occlusion (MCAO) was carried out using the intraluminal thread technique as described previously (Zea Longa, et. al., 1989). Animals were maintained normothermic throughout the surgical procedure, allowed to recover for 1h in an incubator, before being singly housed. Only those animals with a neurological score of 3 1h post-occlusion were included in the study (as assessed using a 5-point scoring system: 0, no deficit; 1, contralateral reflex; 2, weakened grip; 3, circling; 4, immobile; 5, dead). Animals were maintained for up to 1 week at which time animals were killed by transcardial perfusion of 0.9% saline followed by 4% paraformaldehyde in 100mM phosphate buffer. The brains were post-fixed in 4% paraformaldehyde at 4°C for 48h at which time they were removed from the skulls and cut into 2mm blocks using a rat brain matrix. The 2mm sections were then paraffin embedded using a Shandon Citadel 1000 tissue processor, cut into 6µm sections using a

- 5 microtome and mounted on poly-L-lysine coated slides. Sections were then processed for Cresyl Fast Violet (CFV) staining.

#### *Dosing regime*

- Anti-MAG monoclonal antibody and mouse IgG1 isotype control antibody were  
10 dialysed against sterile 0.9 % sodium chloride overnight and concentrated appropriately.  
Study 1 : Animals received 2.5µg of anti-MAGmab or 2.5µg mouse IgG i.c.v. 1, 24 and  
72h following MCAO (5ul per dose).  
Study 2 : Animals received 200µg of anti-MAG mab or 200µg mouse IgG i.v. 1 and 24  
following MCAO.  
15 Investigator was blinded to the identity of each dosing solution.

#### *Neurological assessment*

- Prior to induction of cerebral ischaemia, rats for Study 1 received training in beam  
walking and sticky label test. Animals not reaching criteria in both tests were excluded  
20 from further study. Following training, the remainder of the animals were stratified  
according to performance into two balanced groups. Throughout the neurological  
assessment, the investigators were blinded to the treatment group of the animal.

25

#### *Bilateral Sticky label test*

- The bilateral sticky label test (Schallert et al., Pharmacology Biochemistry and  
Behaviour 16 : 455-462, (1983)) was used to assess contralateral neglect/ipsilateral bias.  
This models tactile extinction observed in human stroke patients (Rose, et al. 1994). This  
30 test has been described in detail previously (Hunter, et al., Neuropharmacology 39 : 806-  
816 (2000); Virley et al Journal of Cerebral Blood Flow & Metabolism, 20 : 563-582  
(2000)). Briefly, a round, sticky paper label was placed firmly around the hairless area  
of the forepaws with equal pressure with order of placement randomised (left, right).  
Training sessions were conducted for 6 days prior to MCAO, day 6 data was utilised as  
35 the pre-operative baseline (Day 0). Animals were given two trials 24 and 7d following  
MCAO, the data represents a mean of the two trials. The latency to contact and remove

- 5 the labels were recorded and analysed using the logrank test (Cox, J. Royal Statistical Society B 34 : 187-220 (1972)).

#### *Beam walking*

- Beam walking was used as a measure of hind-limb and fore-limb co-ordination by  
 10 means of distance travelled across an elevated 100cm beam (2.3cm diameter, 48 cm off the floor) as previously described in detail (Virley et al Journal of Cerebral Blood Flow & Metabolism, 20 : 563-582 (2000)). Rats were trained to cross the beam from start to finish. For testing, each rat was given 2 trials 24 h and 7d following MCAO, the data represents a mean of the two trials. Statistical analysis was ANOVA followed by  
 15 Student's t-test.

#### *The 27-point neurological score (Study-1)*

- This study consists of a battery of tests to assess neurological status including, paw placement, visual forepaw reaching, horizontal bar, contralateral rotation, inclined  
 20 plane, righting reflex, contralateral reflex, motility & general condition, as described previously (Hunter, et al. Neuropharmacology 39 : 806-816 (2000)) with the addition of grip strength measurements (scores 2 for good right fore-limb grip, 1 for weak grip). Total score = 27 for normal animal.

- For study 2 this test was modified further : Grip strength - normal scores 3, good –  
 25 2, weak – 1, very weak – 0; Motility - normal scores 4, excellent – 3, very good – 2, good – 1, fair – 0; General Condition - normal scores 4, excellent – 3, very good – 2, good – 1, fair – 0; Circling – none scores 5, favours one-side scores 4, large circle – 3, medium circle – 2, small circle – 1, spinning – 0). Total score = 32 for a normal animal.

- 30 In both studies animals were tested 1, 24, 48h and 7d following MCAO, a healthy normal animal scores 27 or 32 respectively. Data are presented as median values, Statistical analysis was Kruskal Wallis ANOVA.

#### *Lesion assessment*

- Study 1 - For each animal, lesion areas were assessed in sections from three pre-determined levels in the brain (0, -2.0 and -6.0 mm from Bregma respectively). Neuronal

- 5 damage was assessed using cresyl fast violet staining and the area of damage measured using an Optimas 6.1 imaging package. Data is expressed as mean area ( $\text{mm}^2$ )  $\pm$  sem.
- Study 2 - For each animal, lesion areas were assessed in sections from seven pre-determined levels in the brain (+3mm to -8mm w.r.t. Bregma). Neuronal damage was assessed using cresyl fast violet staining and the area of damage measured using an
- 10 Optimas 6.1 imaging package. Data is expressed as mean area ( $\text{mm}^2$ )  $\pm$  sem.

## Results

### Study 1 – Intra-cerebral ventricular (i.c.v.) administration of anti-MAG mab

#### 15 *Neurological score*

- One hour following MCAO animals in both treatment groups showed marked impairment in neurological score (median score 12 in each group). There was no significant difference between groups at this time. However, 24 ( $p=0.02$ ), 48 ( $p=0.005$ ) h and 7d ( $p=0.006$ ) following MCAO animals treated with anti-MAG mab (2.5  $\mu\text{g}$ , 1, 24 and 72h post-MCAO) showed significantly improved Total Neurological score compared to those treated with control IgG. Median neurological scores 24, 48h and 7d following MCAO in the IgG<sub>1</sub> treated group were 15, 14 and 18 respectively compared to 19.5, 21.5 and 22 in the anti-MAG mab treated animals. On further analysis of the individual behaviours comprising the total score, this significant improvement was mainly attributed
- 25 to improved performance in the following tests : paw placement (24h,  $p=0.045$ ; 48h,  $p=0.016$ ; 7d,  $p=0.008$ ), grip strength (24h,  $p=0.049$  48h,  $p=0.0495$ ; 7d,  $p=0.243$ ), motility (24h,  $p=0.199$ ; 48h,  $p=0.012$ ; 7d,  $p=0.067$ ), horizontal bar (24h,  $p=0.065$ ; 48h,  $p=0.005$ ; 7d,  $p=0.016$ ), inclined plane (24h,  $p=0.006$ ; 48h,  $p=0.006$ ; 7d,  $p=0.169$ ), visual forepaw reaching (48h,  $p=0.049$ , 7d,  $p=0.049$ ) and the degree of circling (24h,  $p=0.417$ ; 48h,
- 30  $p=0.034$ ; 7d,  $p=0.183$ ).

#### 35 *Beam Walking*

Prior to surgery all animals were trained to cross the beam (100cm). Twenty four hours following surgery there was a significant impairment on the distance travelled on

5 the beam in both anti-MAG ( $50 \pm 18$ cm) and IgG<sub>1</sub> ( $22 \pm 14$ cm) treated animals compared to pre-operative values. Although not significant, anti-MAG treated animals showed marked improvement over IgG<sub>1</sub> treated animals in that they travelled twice the distance of IgG<sub>1</sub> treated animals 24h following tMCAO. Seven days following surgery however, while both groups showed marked improvement over time, the performance of animals treated  
10 with IgG remained significantly impaired compared to baseline ( $55 \pm 15$ cm;  $p=0.005$ ). In contrast however 7d following MCAO, animals treated with anti-MAG mab ( $2.5 \mu\text{g}$  1, 24 and 72h, i.c.v post MCAO) performance was not significantly different from baseline ( $75 \pm 15$ cm;  $p=0.07$ ). This data shows that anti-MAG mab treatment accelerated recovery of this beam walking task compared to mouse IgG<sub>1</sub> treated controls.

15

*Sticky label*

Prior to surgery, animals in each of the treatment groups rapidly contacted and removed the labels from each forepaw, there was no significant difference in the groups prior to treatment (Table 1). Twenty-four hours and 7d following MCAO the latency to  
20 contact the left paw in each of the treatment groups remained relatively unaltered, while that of the right was markedly increased. However there was no significant differences between removal times in anti-MAG and IgG<sub>1</sub> treated animals. In addition 24h following MCAO, the latency to removal from both the left and right forepaw was significantly increased in both treatment groups compared to baseline, however in anti-MAG treated  
25 animals the latency to removal from the left paw was significantly shorter than that of IgG<sub>1</sub> treated animals ( $p=0.03$ ). There was also a trend for reduced latency to removal from the right paw in anti-MAG treated animals compared to those treated with IgG<sub>1</sub> ( $p=0.08$ ) (Table 1). At 7d there was some degree of recovery in IgG<sub>1</sub> treated animals in that the latency to removal times for each forepaw were reduced compared to those at 24h  
30 (Table 1). This data suggests that treatment of rats with anti-MAG mab accelerate the recovery in this sticky label test following tMCAO.

35

5

Table 1 – Sticky label data

Day	Treatment	Contact Time (s) (Mean±sem)		Removal Time (s) (Mean±sem)	
		Left Forepaw	Right Forepaw	Left Forepaw	Right Forepaw
0	Anti-MAG	2.4 ± 0.2	3.6 ± 0.5	12 ± 2	12 ± 2
0	IgG <sub>1</sub>	3.3 ± 0.6	4.2 ± 0.7	10 ± 1	9 ± 1
1	Anti-MAG	5.9 ± 3.7	109.6 ± 27.5	*61 ± 26	96 ± 26
1	IgG <sub>1</sub>	3.6 ± 0.5	71.8 ± 31.7	130 ± 21	156 ± 19
7	Anti-MAG	3.8 ± 1	36.4 ± 10.2	54 ± 23	80 ± 30
7	IgG <sub>1</sub>	2.8 ± 0.3	64 ± 28	23 ± 8	87 ± 20

(\*p=0.03 Anti-MAG v's IgG<sub>1</sub> using the logrank test)*Lesion area measurements*

10 Administration of anti-MAG mab i.c.v, significantly reduced lesion area in two of the three brain levels examined compared to those animals treated with equal amounts of mouse IgG<sub>1</sub> when examined 7 days following tMCAO (Table 2).

Table 2

Treatment	Mean Lesion Area ± sem (mm <sup>2</sup> ) 7d following tMCAO		
	0 mm wrt Bregma	-2 mm wrt Bregma	-6 mm wrt Bregma
Anti-MAG mab (n=8)	*9 ± 2	<sup>s</sup> 4 ± 3	<sup>#</sup> 3 ± 1
Mouse IgG <sub>1</sub> (n=9)	14 ± 1	12 ± 1	5 ± 1

15 (\*p=0.02, <sup>s</sup>p=0.03, <sup>#</sup>p=0.06, anti-MAG v's IgG<sub>1</sub>, One-way, unpaired Students T-Test)

**Study 2 – Intra-venous (i.v.) administration***Neurological score*

20 One and 24 hours following MCAO animals in both groups showed marked impairment in neurological score. There was no significant difference between groups at this time, median scores 24h following anti-MAG mab and IgG<sub>1</sub> treatment were 20 and 18 respectively (p=0.5). Forty-eight hours following MCAO, animals treated with anti-MAG mab (200ug, i.v. 1 and 24h post-MCAO) showed significant improvement in paw placement (p=0.048) and grip strength (p=0.033). Seven days following the onset of

- 5 cerebral ischaemia animals treated with anti-MAG mab continued to improve (paw placement  $p=0.041$ ; grip strength,  $p=0.048$ ; motility,  $p=0.05$ ) and showed significant improvement in total neurological score (median score 25) compared to those treated with mouse IgG<sub>1</sub> (Median score 23,  $p=0.047$ ).

10

#### *Lesion area measurements*

The anti-MAG antibody when administered i.v. MCAO significantly reduced lesion area at 5 out of 7 pre-determined brain levels (+3 to -8 mm w.r.t. Bregma) compared to isotype controls, when examined 7d following MCAO.

15

Brain level wrt Bregma	Mean lesion area $\pm$ SEM (mm <sup>2</sup> ) – Anti- MAG treated	Mean lesion area $\pm$ SEM (mm <sup>2</sup> ) – Mouse IgG <sub>1</sub> treated
3 mm	*0.38 $\pm$ 0.27	1.77 $\pm$ 0.45
1 mm	*5.82 $\pm$ 1.65	9.627 $\pm$ 1.14
-1 mm	8.98 $\pm$ 2.58	12.07 $\pm$ 1.57
-2 mm	7.28 $\pm$ 1.92	10.04 $\pm$ 1.87
-4 mm	*5.57 $\pm$ 1.06	10.38 $\pm$ 1.39
-6 mm	*1.36 $\pm$ 0.51	4.43 $\pm$ 1.95
-8 mm	*0.27 $\pm$ 0.27	1.93 $\pm$ 0.56

\*  $p < 0.05$  – Unpaired, one-way Students T-test

#### **Conclusions**

- 20 An anti-MAG monoclonal antibody administered either directly into the CSF or intravenously following transient middle-cerebral artery occlusion in the rat, both reduced the area of cell death and improved functional recovery compared to control treated animals. The degree of neuroprotection seen in these studies suggests that this effect can not be attributed to axonal sprouting as this would not result in neuronal sparing. The improvement in functional recovery seen 24 and 48h following MCAO probably reflects
- 25 the degree of neuroprotection offered by this antibody compared to control treated animals. However, over time the animals appear to improve further, suggesting that blocking MAG activity can also enhance functional recovery over time.

The studies presented here provide evidence that blocking the actions of MAG provide both neuroprotection and enhanced functional recovery in a rat model of stroke,



5 and therefore anti-MAG antibodies or MAG antagonists provide potential therapeutic agents for acute neuroprotection and/or the promotion of functional recovery following stroke. Anti-MAG antibodies or MAG antagonists also have potential use in the treatment of other neurological disorders where the degeneration of cells and or nerve fibres is apparent such as spinal cord injury, traumatic brain injury, peripheral  
10 neuropathy, Alzheimer's disease, fronto-temporal dementias (tauopathies), Parkinson's disease, Huntington's disease and Multiple Sclerosis.

### **Example 2 – Chimeric antibody**

15 Altered antibodies include chimeric antibodies which comprise variable regions deriving from one species linked to constant regions from another species. An example of a mouse-human chimeric anti-MAG antibody of the invention is provided in Figures 5 and 6. Mouse-human chimeras using human IgG1, IgG2, IgG3, IgG4, IgA, IgE, IgM or IgD constant regions may be produced, as may chimeras associating the mouse variable  
20 regions with heavy or light chain constant regions from non-human species.

Figure 5 provides the amino acid sequence of a chimeric immunoglobulin heavy chain in which the murine anti-MAG variable region is associated with a functional immunoglobulin secretion signal sequence, and with an altered form of the human IgG1  
25 constant region, in which Kabat residues 248 and 250 have been mutated to alanine in order to disable the effector functions of binding to FcγRI and complement protein C1q (Duncan, A.R. and Winter, G. Localization of the C1q binding site on antibodies by surface scanning. Nature 332, 738-740, 1988. Duncan, A.R., Woelf, J.M., Partridge, L.J., Burton, D.R. and Winter, G. Localisation of the binding site for human FcR1 on  
30 IgG. Nature 332, 563-564, 1988). Such mutations are optionally made in order to customise the properties of an altered antibody to achieve a particular therapeutic effect – for example binding to and blocking the function of an antigen without activating lytic effector mechanisms. Other altered antibodies of the invention use human constant regions without such disabling mutations.

35

- 5 Figure 6 provides the amino acid sequence of a chimeric immunoglobulin light chain in which the murine anti-MAG variable region is associated with a functional immunoglobulin secretion signal sequence, and with the human kappa constant region.

From the information provided in Figures 5 and 6, cDNA inserts encoding these chimeric  
10 chains may be prepared by standard molecular biology techniques well known to those skilled in the art. Briefly, the genetic code is used to identify nucleotide codons encoding the desired amino acids, creating a virtual cDNA sequence encoding the chimeric protein. If the cDNA insert is desired to be expressed in a particular organism, then particularly favoured codons may be selected according to known codon usage biases. The desired  
15 nucleotide sequence is then synthesised by means of PCR amplification of a template comprising overlapping synthetic oligonucleotides which, as a contig, represent the desired sequence. The resulting product may also be modified by PCR or mutagenesis to attach restriction sites to facilitate cloning into a plasmid for expression or further manipulations.

20

## 5 CLAIMS

1. A method of treatment or prophylaxis of stroke and other neurological diseases in a human which comprises administering to said human in need thereof an effective amount of a MAG antagonist or anti-MAG antibody, including altered antibodies or a functional fragment thereof.
2. The use of a MAG antagonist or anti-MAG antibody, including altered antibodies or a functional fragment thereof in the preparation of a medicament for treatment or prophylaxis of stroke and other neurological diseases.
3. A method of inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering, or at risk of developing, a stroke or other neurological disease which comprises administering to said human in need thereof an effective amount of a MAG antagonist or anti-MAG antibody, including altered antibodies or a functional fragment thereof.
4. The use of a MAG antagonist or anti-MAG antibody, including altered antibodies or a functional fragment thereof in the preparation of a medicament for inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering from, or at risk of developing, a stroke and other neurological disease.
5. An altered anti-MAG antibody and functional fragments thereof.
6. An altered anti-MAG antibody or functional fragment thereof which comprises:
  - a) an antibody light chain variable domain comprising a light chain of an acceptor monoclonal antibody having at least one of the CDRs of the antigen binding domain substituted by the CDRs of the antigen binding domain of the light chain of a non-human donor monoclonal antibody that specifically binds to MAG and/or
  - b) an antibody heavy chain variable domain comprising a heavy chain of an acceptor monoclonal antibody having at least one of the CDRs of the antigen binding domain substituted by the CDRs of the antigen binding domain of the

5 heavy chain of a non-human donor monoclonal antibody that specifically binds to MAG.

7. An altered antibody or functional fragment thereof which comprises one or more of the following CDR's.

10

***Light chain CDRs***

<b><i>CDR</i></b>	<b><i>According to Kabat</i></b>	<b><i>According to Chothia&amp;Lesk</i></b>
L1	KSSHSVLYSSNQKNYLA	SHSVLYSSNQKNY
L2	WASTRSE	WAS
L3	HQQLSSYT	HQQLSSY

***Heavy chain CDRs***

15

<b><i>CDR</i></b>	<b><i>According to Kabat</i></b>	<b><i>according to Chothia&amp;Lesk</i></b>
H1	NYNMN	GYTFTNYNM
H2	WINTYTGEPTYADDFKT	TYTG
H3	NPINYYGINYEGYVMDY	

8. An altered antibody or functional fragment thereof according to claim 7 which comprises a heavy chain variable domain which comprises one or more CDR's selected from CDRH1, CDRH2 and CDRH3 and/or a light chain variable domain which comprises one or more CDRs selected from CDRL1, CDRL2 and CDRL3 .
- 20

9. An altered anti-Mag antibody according to claim 8 or functional fragment thereof which comprises:

25 a heavy chain variable domain ( $V_H$ ) which comprises in sequence hypervariable regions CDRH1, CDRH2 and CDRH3  
and /or  
a light chain variable domain ( $V_L$ ) which comprises in sequence hypervariable regions CDRL1, CDRL2 and CDRL3.

5

10       An antibody of claim 7 which is monoclonal.

10   11       An antibody of claim 7 or 8 which is humanised.

12.   A pharmaceutical composition comprising an antibody according to any of claims 5-12 or a functional fragment thereof together with a pharmaceutically acceptable carrier.

15

13.   A method of treatment or prophylaxis of stroke and other neurological diseases in a human which comprises administering to said human in need thereof an effective amount of an anti-MAG antibody, according to claims 5-12 including altered or a functional fragment thereof.

20

14. The use of an anti-MAG antibody according to claims 5-12 or a functional fragment thereof in the preparation of a medicament for treatment or prophylaxis of stroke and other neurological diseases.

25   15. A method of inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering, or at risk of developing, a stroke or other neurological disease which comprises administering to said human in need thereof an effective amount of an anti-MAG antibody according to claims 5-12 or a functional fragment thereof.

30

16. The use of an anti-MAG antibody according to claims 5-12 or a functional fragment thereof in the preparation of a medicament for inhibiting neurodegeneration and/or promoting functional recovery in a human patient suffering from, or at risk of developing, a stroke and other neurological disease.

35

**IgG 284926**

**CDRI-L**

**CDR2-L**

NIMMTQSPSSLAVSAGEKVTMSC**KSSH**SVLYSSN  
24 34  
**QKNYLA**WYQQKPGQSPKLLIY**WASTRSE**GVPR

## Variable chain

FTGSGSGTDFTLTINVHTEDLAVYYCHQQLSSYTF

95 → 103

GGGTTKLEIK---

**CDR3-L**

---RADAAPTVSIFPPSSEQLTSGGASVVCFLNNFYPKDIN  
VKWKIDGSEKQNGVLNSWTDQDSKDSTYSMSSTLTL  
TKDEYERHNSYTCEAHTKSTSPIVKSENNEC

## Constant chain

VARIABLE HEAVY CHAIN *CDR1-H*

EIQLVQSGPE(L)KKPGETNKISKASGYTFTN<sup>30</sup>**NYN**<sup>34</sup>**MMN**<sup>36</sup>**WV** *CDR2-H*  
 KQAPGKGLKWMG**W**<sup>49</sup>**INTYTG**<sup>66</sup>**EPTYADDFKT**<sup>68</sup>**NFA**  
 FSLETSASTAYLQISNLKNEDTATYFCAR**NP**<sup>88</sup>**INYYGIN**<sup>97</sup>**YEGYV** *CDR3-H*

Variable  
Chain

**MDY**WGQGTSTVTV(SE)A---

Constant  
Chain

---KTTPPSVYPLAPGSAAQTNSMVTLGCLVKGYFPEP  
 VTVTWNSGSLSSGVHTFP AVLQSDL YTLSSSVTVPPSS  
 TWPSETVTCNV AHPASSTKVDK KIVPRDCGCKPCICT  
 VPEVSSVFIFPPKPKDVL TITLTPK VTCVVVDISKDDPE  
 VQFSWFVDDVEVHTAQTQPREEQFNSTFRSVSELPIM  
 HQDWLNGKEFKCRVNSA AFPAPIEKTISKTKGRPKAP  
 QVYTIPPPKEQMAKDKVSLTCMITDFFREDITVEWQW  
 NGQPAENYKNTQPIMDTDGSYFVYSKIN VQKSNWEA  
 GNTFTCSVLHEGLHNHHTEKSLSHSPGK

**FIGURE 3***Light chain V-region (336bp)*

AACATCATGATGACCCAGAGCCCCAGCAGCCTGGCCGTGAGCGCCGGCGAGAAGGTGACCAT  
GAGCTGCAAGAGCAGCCACAGCGTGCTGTACAGCAGCAACCAGAAGAAGTACCTGGCCTG  
GTACCAGCAGAAGCCCGGCCAGAGCCCCAAGCTGCTGATCTACTGGGCCAGCACCCGCAGC  
GAGGGCGTGCCCGACCGCTTCACCGGCAGCGGCAGCGGCACCGACTTCACCCTGACCATCATC  
AACGTGCACACCGAGGACCTGGCCGTGTACTACTGCCACCAGCAGCTGAGCAGCTACACCTT  
CGGCGGCGGCACCAAGCTGGAGATCAAG

**FIGURE 4***Heavy chain (381bp) V-region*

GAGATCCAGCTGGTGCAGAGCGGCCCGAGCTGAAGAAGCCCGGCGAGACCAACAAGATCA  
GCTGCAAGGCCAGCGGCTACACCTTCACCAACTACAACATGAACTGGGTGAAGCAGGCCCCC  
GGCAAGGGCCTGAAGTGGATGGGCTGGATCAACACCTACACCGGCGAGCCCACCTACGCCG  
ACGACTTCAAGACCAACTTCGCCTTCAGCCTGGAGACCAGCGCCAGCACCGCCTACCTGCAGA  
TCAGCAACCTGAAGAACGAGGACACCGCCACCTACTTCTGCGCCCGCAACCCCATCAACTACT  
ACGGCATCAACTACGAGGGCTACGTGATGGACTACTGGGGCCAGGGCACCAGCGTGACCGT  
GAGCGAGGCC



Figure 5

MAWWTLLFLMAAAQSAEIQLVQSGPELKKPGETNKISCKASGYTFTNYNMNWVKQAPGKGLKWMG  
WINTYTGEPTYADDFKTNFAFSLETSASTAYLQISNLKNEDTATYFCARNPINYYGINYEGYVMDY  
WGQGTSTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTWSWNSGALTSGVHTFPA  
VLQSSGLYSLSSVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELAGAP  
SVFLFPPKPKDTLMISRTPEVTCVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRWVS  
VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVK  
GFYPSDIAVEWESNGQPENNYKTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFCFSVMHEALHNHY  
TQKSLSLSPGK

Figure 6

MGWSCIIHFLVATATGVHSNIMMTQSPSSSLAVSAGEKVTMSCKSSHSVLYSSNQKNYLAWYQQKPG  
QSPKLLIYWASTRSEGVPDRFTGSGSGTDFLTIIINVHTEDLAVYYCHQQLSSYTFGGGKLEIKR  
TVAAPSVFIFPPSDEQLKSGTASVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYS  
LSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC